A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers
A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers Prostate Cancer and Prostatic Diseases advance online publication, February 17 2015. doi:10.1038/pcan.2015.4 Authors: M E Schutzer, P F Orio, M C Biagioli, D A Asher, H Lomas &D Moghanaki
Conclusions: BT combined with HT can increase the bPFS rates of patients with localized prostate cancer, but it does not improve patients' OS rates.
Condition: Prostate Cancer Interventions: Drug: 68-Ga RM2.; Drug: 68-Ga PSMA11; Device: PET/MRI Sponsor: Andrei Iagaru Recruiting
iot S, Pasquier D Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80% of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial prostate specific antigen serum concentration value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controvers...
For patients with localised prostate cancer, radical radiotherapy can be delivered with either external beam radiotherapy (EBRT) or brachytherapy (BT). Compared to EBRT, BT dosimetry offers the optimum in conformality, an unrivalled dose drop-off gradient beyond the gland markedly sparing normal tissues and enables extreme dose intensification to the prostate. Several randomised controlled trials have shown dose-escalation to significantly improve biochemical control [1 –5] and brachytherapy offers the most effective means of achieving this.
CONCLUSION: This is the largest cohort of single dose HDR brachytherapy patients treated with a single dose published to date. It shows that with 19 Gy there is 100% bRFS at 3 years in low risk patients but results in intermediate and high risk groups are less encouraging falling to 86% and 75% at 3 years with relapse predominantly in the prostate. Limited by the short follow up period of this study, the long-term outcomes of this single dose HDR approach remains uncertain. It is important to have close ongoing surveillance of this cohort as the data matures. PMID: 32044166 [PubMed - as supplied by publisher]
We present an automatic bi-objective parameter-tuning approach for inverse planning methods for high-dose-rate prostate brachytherapy, which aims to overcome the difficult and time-consuming manual parameter tuning that is currently required to obtain patient-specific high-quality treatment plans. We modelled treatment planning as a bi-objective optimization problem, in which dose-volume-based planning criteria related to target coverage are explicitly separated from organ-sparing criteria. When this model is optimized, a large set of high-quality plans with different trade-offs can be obtained. This set can be visualized ...
Conditions: Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8 Interventions: Radiation: High-Dose Rate Brachytherapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Stereotactic Ablative Radiotherapy Sponsors: Rutgers, The&...